scholarly journals The Adaptation, Face, and Content Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease

2016 ◽  
Vol 19 (5) ◽  
pp. 549-555 ◽  
Author(s):  
Jason W. Boland ◽  
Carla Reigada ◽  
Janelle Yorke ◽  
Simon P. Hart ◽  
Sabrina Bajwah ◽  
...  
Thorax ◽  
2017 ◽  
Vol 73 (9) ◽  
pp. 880-883 ◽  
Author(s):  
Miriam J Johnson ◽  
Armita Jamali ◽  
Joy Ross ◽  
Caroline Fairhurst ◽  
Jason Boland ◽  
...  

The inter-rater/test–retest reliability and construct validity of a palliative care needs assessment tool in interstitial lung disease (NAT:PD-ILD) were tested using NAT:PD-ILD-guided video-recorded consultations, and NAT:PD-ILD-guided consultations, and patient and carer-report outcomes (St George’s Respiratory Questionnaire (SGRQ)-ILD, Carer Strain Index (CSI)/Carer Support Needs Assessment Tool (CSNAT)). 11/16 items reached at least fair inter-rater agreement; 5 items reached at least moderate test–retest agreement. 4/6 patient constructs demonstrated agreement with SGRQ-I scores (Kendall’s tau-b, 0.24–20.36; P<0.05). 4/7 carer constructs agreed with the CSI/CSNAT items (kappa, 0.23–20.53). The NAT:PD-ILD is reliable and valid. Clinical effectiveness and implementation are to be evaluated.


Thorax ◽  
2016 ◽  
Vol 71 (Suppl 3) ◽  
pp. A266.1-A266
Author(s):  
C Reigada ◽  
C Fairhurst ◽  
J Yorke ◽  
J Ross ◽  
J Boland ◽  
...  

Thorax ◽  
2017 ◽  
Vol 72 (11) ◽  
pp. 1049-1051 ◽  
Author(s):  
C Reigada ◽  
A Papadopoulos ◽  
J W Boland ◽  
J Yorke ◽  
J Ross ◽  
...  

QJM ◽  
2021 ◽  
Author(s):  
Rituparna Saha ◽  
David T Ryan ◽  
Niall McVeigh ◽  
John F Garvey ◽  
Silke Ryan ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Valentina Gonzalez-Jaramillo ◽  
Jelena Guyer ◽  
Nora Luethi ◽  
Piotr Sobanski ◽  
Rut Zbinden ◽  
...  

Abstract Background The Needs Assessment Tool: Progressive Disease-Heart Failure (NAT: PD-HF) is a tool created to assess the needs of people living with heart failure and their informal caregivers to assist delivering care in a more comprehensive way that addresses actual needs that are unmet, and to improve quality of life. In this study, we aimed to (1) Translate the tool into German and culturally adapt it. (2) Assess internal consistency, inter-rater reliability, and test–retest reliability of the German NAT: PD-HF. (3) Evaluate whether and how patients and health care personnel understand the tool and its utility. (4) Assess the tool’s face validity, applicability, relevance, and acceptability among health care personnel. Methods Single-center validation study. The tool was translated from English into German using a forward–backward translation. To assess internal consistency, we used Cronbach´s alpha. To assess inter-rater reliability and test–retest reliability, we used Cohen´s kappa, and to assess validity we used face validity. Results The translated tool showed good internal consistency. Raters were in substantial agreement on a majority of the questions, and agreement was almost perfect for all the questions in the test–retest analysis. Face validity was rated high by health care personnel. Conclusion The German NAT: PD-HF is a reliable, valid, and internally consistent tool that is well accepted by both patients and health care personnel. However, it is important to keep in mind that effective use of the tool requires training of health care personnel.


2021 ◽  
Vol 11 ◽  
Author(s):  
Mai Sasaki Aanensen Fraz ◽  
Natasha Moe ◽  
Mona-Elisabeth Revheim ◽  
Maria L. Stavrinou ◽  
Michael T. Durheim ◽  
...  

Common variable immunodeficiency (CVID) is characterized not only by recurrent bacterial infections, but also autoimmune and inflammatory complications including interstitial lung disease (ILD), referred to as granulomatous-lymphocytic interstitial lung disease (GLILD). Some patients with GLILD have waxing and waning radiologic findings, but preserved pulmonary function, while others progress to end-stage respiratory failure. We reviewed 32 patients with radiological features of GLILD from our Norwegian cohort of CVID patients, including four patients with possible monogenic defects. Nineteen had deteriorating lung function over time, and 13 had stable lung function, as determined by pulmonary function testing of forced vital capacity (FVC), and diffusion capacity of carbon monoxide (DLCO). The overall co-existence of other non-infectious complications was high in our cohort, but the prevalence of these was similar in the two groups. Laboratory findings such as immunoglobulin levels and T- and B-cell subpopulations were also similar in the progressive and stable GLILD patients. Thoracic computer tomography (CT) scans were systematically evaluated and scored for radiologic features of GLILD in all pulmonary segments. Pathologic features were seen in all pulmonary segments, with traction bronchiectasis as the most prominent finding. Patients with progressive disease had significantly higher overall score of pathologic features compared to patients with stable disease, most notably traction bronchiectasis and interlobular septal thickening. 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/CT (PET/CT) was performed in 17 (11 with progressive and six with stable clinical disease) of the 32 patients and analyzed by quantitative evaluation. Patients with progressive disease had significantly higher mean standardized uptake value (SUVmean), metabolic lung volume (MLV) and total lung glycolysis (TLG) as compared to patients with stable disease. Nine patients had received treatment with rituximab for GLILD. There was significant improvement in pathologic features on CT-scans after treatment while there was a variable effect on FVC and DLCO.ConclusionPatients with progressive GLILD as defined by deteriorating pulmonary function had significantly greater pathology on pulmonary CT and FDG-PET CT scans as compared to patients with stable disease, with traction bronchiectasis and interlobular septal thickening as prominent features.


2018 ◽  
Vol 56 (4) ◽  
pp. 602-612 ◽  
Author(s):  
Victoria L. Allgar ◽  
Hong Chen ◽  
Ed Richfield ◽  
David Currow ◽  
Una Macleod ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document